Ion AmpliSeq reagents

The National Institutes of Health intends to award a Firm Fixed-Price Purchase Order to Life Technologies Corporation for Ion AmpliSeq reagents. The reagents are required for the identification of transcriptional biomarkers from blood of Alcohol Use Disorder patients and controls as part of an ongoing study. Although this notice is not a request for competitive quotes, small businesses may submit a written capability statement to demonstrate their ability to perform the requirement. • The AmpliSeq Transcriptome reagents and associated sequencing reagents are required for the study. • The reagents should be able to handle low input quantities of RNA and degraded samples. • The contract is expected to be awarded approximately 10 days after the notice date. • Small businesses may submit a written capability statement to demonstrate their ability to perform the requirement.